CTCL Phase IIA Study on therapy with the NF-kB inhibiting and apoptosis inducing drug dimethylfumarate (DMF) in patients with Cutaneous T cell lymphoma (CTCL) (Aktiv)
REDIRECT Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (Aktiv)